Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (22)

2023

  1. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  2. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  3. Mutated trimeric RBD vaccines: a platform against variants of concern

    Signal Transduction and Targeted Therapy

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

2021

  1. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

  2. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  4. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

  5. The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?

    Cancers, Vol. 13, Núm. 13

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

2015

  1. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

  3. Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance

    Liver Transplantation, Vol. 19, Núm. 9, pp. 937-944

2012

  1. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

  2. Dendritic cells: Nearly 40 years later

    Inmunologia

  3. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

    International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651

2011

  1. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159